HSHC

Updated 5 days ago
  • Age: 23 years
  • ID: 14948566/133
4F, No. 88, Sec. 1, Neihu Rd., Neihu Dist. Taipei 11493, Taiwan
Stage III (2009-present) HDD technology has also been applied in the development of a new drug product which is a tailored combination of hyaluronic acid and an existing drug. Our product, IBD98-M, is an oral capsule designed for IBD patients and is a mixture of hyaluronic acid and mesalamine... Stage IV (2013-present) In this latest stage we have developed "Hyaluronic Acid Conjugated Drugs (HACD)" where a drug molecule is conjugated onto the hyaluronic acid polymer. Using this technology we have developed a new drug product, CA102N, which is a novel receptor targeted chemotherapy designed for cancer treatment... Holy Stone Healthcare Co., Ltd. (4194.TW), established in Taipei in January 2001, is a subsidiary of Holy Stone Enterprise (3026.TW). Since 2009, the company has focused on a biopolymer drug delivery platform. Our R team has successfully developed "Hyaluronan Drug Delivery (HDD)" technology, which is a composition of hyaluronic acid in combination with a drug. This..
Also known as: Holy Stone Healthcare, Holy Stone Healthcare Co., Ltd.
Primary location: Taipei Taiwan
  • 0
  • 0
Interest Score
1
HIT Score
0.00
CEO
Domain
hshc.com.tw

Actual
www.hshc.com.tw

IP
125.227.102.218

Status
OK

Category
Company
0 comments Add a comment